Distinguishing Progression from Pseudoprogression in Glioblastoma Using 18 F-Fluciclovine PET.
Autor: | Nabavizadeh A; Department of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania; ali.nabavizadeh@pennmedicine.upenn.edu., Bagley SJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania., Doot RK; Department of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania., Ware JB; Department of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania., Young AJ; Department of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania., Ghodasara S; Department of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania., Zhao C; Department of Surgery, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Anderson H; Department of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania., Schubert E; Department of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania., Carpenter EL; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania., Till J; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania., Henderson F Jr; Department of Neurosurgery, Loma Linda University Medical Center, Loma Linda, California., Pantel AR; Department of Radiology, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania., Chen HI; Department of Neurosurgery, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania; and., Lee JYK; Department of Neurosurgery, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania; and., Amankulor NM; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.; Department of Neurosurgery, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania; and., O'Rourke DM; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.; Department of Neurosurgery, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania; and., Desai A; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania., Nasrallah MP; Division of Neuropathology, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Brem S; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.; Department of Neurosurgery, Hospital of University of Pennsylvania, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania; and. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2023 Jun; Vol. 64 (6), pp. 852-858. Date of Electronic Publication: 2022 Dec 22. |
DOI: | 10.2967/jnumed.122.264812 |
Abstrakt: | Accurate differentiation between tumor progression (TP) and pseudoprogression remains a critical unmet need in neurooncology. 18 F-fluciclovine is a widely available synthetic amino acid PET radiotracer. In this study, we aimed to assess the value of 18 F-fluciclovine PET for differentiating pseudoprogression from TP in a prospective cohort of patients with suspected radiographic recurrence of glioblastoma. Methods: We enrolled 30 glioblastoma patients with radiographic progression after first-line chemoradiotherapy for whom surgical resection was planned. The patients underwent preoperative 18 F-fluciclovine PET and MRI. The relative percentages of viable tumor and therapy-related changes observed in histopathology were quantified and categorized as TP (≥50% viable tumor), mixed TP (<50% and >10% viable tumor), or pseudoprogression (≤10% viable tumor). Results: Eighteen patients had TP, 4 had mixed TP, and 8 had pseudoprogression. Patients with TP/mixed TP had a significantly higher 40- to 50-min SUV (© 2023 by the Society of Nuclear Medicine and Molecular Imaging.) |
Databáze: | MEDLINE |
Externí odkaz: |